Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Neoadjuvant Regimen May Not Require Chemotherapy in Some HER2-Positive Breast Cancer Patients

May 29th 2013

Some HER2-positive breast cancer patients may be able to receive targeted neoadjuvant therapy with lapatinib and trastuzumab without chemotherapy.

Dr. Rugo on Chemotherapy for Metastatic Breast Cancer

May 28th 2013

Hope S. Rugo, MD, professor of medicine and director of breast oncology and clinical trials education at the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses the treatment of patients with metastatic breast cancer with chemotherapy.

Genetic Experts' Views Shift on Testing, Prophylactic Surgery

May 28th 2013

The decision about whether to get tested for a genetic mutation that may predispose a person to certain cancers is a difficult one for many patients to make. Even more difficult for mutation carriers is deciding whether to undergo a prophylactic surgical procedure.

Geriatric Assessments Should Guide Treatment Decisions in Older Patients

May 24th 2013

Breast cancer clinicians today are faced with an ever-expanding number of older patients, yet determining the most appropriate treatment for these individuals can be challenging.

Dr. Borgen on the Decision to be Tested for a BRCA Gene

May 23rd 2013

Patrick Borgen, MD, chair, Department of Surgery, director, Maimonides Breast Cancer Center, discusses a patient's decision to be tested for a BRCA gene.

Chip Petricoin on the Discovery of New Biomarkers

May 20th 2013

Emanuel F. "Chip" Petricoin III, PhD, Co-Director, Center for Applied Proteomics & Molecular Medicine, Professor of Life Sciences, George Mason University, discusses the discovery of new biomarkers in breast cancer.

Resistance Poses Challenges in Chemotherapy Options

May 20th 2013

While chemotherapy might initially be effective in the treatment of patients with metastatic breast cancer, it is very common for patients to develop resistance to such agents.

LUX Program Examines Pan-HER Inhibitor Afatinib in Multiple Tumor Types

May 17th 2013

Researchers are attempting to determine if targeting more than one tyrosine kinase provide a greater benefit in several clinical trials involving the investigational drug afatinib.

A National Dialogue on Genetic Testing for Breast Cancer

May 16th 2013

A high-profile case of a medical decision being based primarily on the results of a genetic test has prompted a national discussion on the benefits and risks associated with acting on the results of such a test.

Sledge Expects "Big Data" to Generate Big Changes

May 15th 2013

The technological advances in analyzing the human genome have spawned a new era in breast cancer as well as other types of malignancies that will affect oncology practice and will necessitate dramatic changes in the clinical trials system.

Dr. Chagpar Discusses Sentinel Node Biopsying

May 15th 2013

Anees Chagpar, MD, MSc, MA, MPH, Associate Professor of Surgery (Oncology), Director, The Breast Center at Smilow Cancer Hospital at Yale-New Haven, gives an overview of the discussion surrounding sentinel node biopsying before and after neoadjuvant chemotherapy.

I-SPY Trials Seek Effective New Drug Combinations Using Adaptive Trial Design

May 14th 2013

The I-SPY trials are designed to test several different experimental therapies at once to determine which ones work best in which patients.

Anticipatory and Delayed Nausea Remain Concerns for Patients on Chemotherapy

May 13th 2013

Despite progress in treating chemotherapy-induced nausea and vomiting, especially in the acute phase up to 24 hours after treatment, the condition is still one of the side effects patients fear most.

Dr. Baselga Discusses Fine Tuning Drug Doses

May 13th 2013

JosÃ© Baselga, MD, PhD, Physician-in-Chief, Memorial Sloan-Kettering Cancer Center, discusses the need to fine tune mTOR and PI3K inhibitor doses.

Deciding When Post-Mastectomy Radiation Therapy Is Warranted

May 10th 2013

For appropriate patients, postmastectomy radiation therapy is associated with improved locoregional control and better survival.

Dr. Muss on Using Tools to Evaluate Older Patients

May 9th 2013

Hyman B. Muss, MD, Professor of Medicine, Director of Geriatric Oncology, Lineberger Comprehensive Cancer Center, discusses evaluation tools for treating older patients.

Counseling BRCA, Lynch Carriers on Prophylactic Oophorectomy

May 8th 2013

Due to the high lifetime risk of ovarian cancer and the poor ovarian cancer surveillance options available, women who carry BRCA1 or BRCA2 mutations are advised to remove their ovaries and fallopian tubes by age 40 or when childbearing is complete.

Dr. von Minckwitz on Breast Cancer Responses

May 7th 2013

Gunter von Minckwitz, MD, PhD, discusses the current unsolved medical situation regarding patients with breast cancer who do not respond to treatment.

Dr. Tripathy Reviews Targeted Therapies in Breast Cancer

May 3rd 2013

Debu Tripathy, MD, from the University of Southern California Norris Comprehensive Cancer Center, discusses the targeted therapies that are currently available for the treatment of patients with breast cancer.

Dr. Carey on the Future of Clinical Trial Design

May 2nd 2013

Lisa A. Carey, MD, Professor of Medicine, University of North Carolina at Chapel Hill, discusses the present and future state of clinical trial design.